This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Complementary/Integrative Medicine for Brain Cancer Patients

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified June 2017 by Noah Samuels, The Chaim Sheba Medical Center
Sponsor:
Information provided by (Responsible Party):
Noah Samuels, The Chaim Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT03185780
First received: June 8, 2017
Last updated: June 11, 2017
Last verified: June 2017
  Purpose

Nearly a quarter of a million patients are diagnosed each year with tumors of the central nervous system, a third of them malignant. The most common malignant tumor of the brain is the high grade glioma( HGG), whose treatment begins with surgical resection of the tumor, followed by a combined chemo-radiation regimen, with the drug Temodal (temozolomide). This treatment is often accompanied by toxic effects (e.g., nausea, headache, constipation, weakness/fatigue, and others), with treatment of these effects limited in their effectiveness and safety. Complementary medicine treatments such as acupuncture and touch therapies (reflexology, Shiatsu, etc.) have been researched and found to be both safe and effective for some of the toxic effects of oncology treatment regimens.

The present pilot study is set to examine the impact of complementary medicine on the toxic effects of the conventional treatment for HGG. The study will include 40 patients and will last for two years, during which patients will be treated with acupuncture and/or touch therapies, this in parallel to their chemo-radiation regimen. The primary study outcome will be the scores on four Patient-Reported Outcome Measures (PROMs): the Measure Yourself Concerns and Wellbeing (MYCAW) study tool; the Functional Assessment of Cancer Therapy, Brain Cancer (FACT-Br) questionnaire; the Edmonton Symptom Assessment Scale (ESAS); and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30). Secondary study outcomes will include the safety of the complementary medicine treatments, and adherence to the planned oncology treatment regimen, as measured by the Relative Dose Intensity (RDI) calculation.


Condition Intervention
Quality of Life Chemotherapeutic Toxicity Radiation Toxicity Other: Acupuncture

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Intervention Model Description:
Patients with high grade glioma undergoing adjuvant (post-surgical) chemo-radiation treatment will be treated with acupuncture and/or touch therapies, this in parallel to their conventional treatment regimen. The primary study outcome will be the scores on four Patient-Reported Outcome Measures (PROMs): the Measure Yourself Concerns and Wellbeing (MYCAW) study tool; the Functional Assessment of Cancer Therapy, Brain Cancer (FACT-Br) questionnaire; the Edmonton Symptom Assessment Scale (ESAS); and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30). Secondary study outcomes will include the safety of the complementary medicine treatments, and adherence to the planned oncology treatment regimen, as measured by the Relative Dose Intensity (RDI) calculation.
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Impact of Complementary/Integrative Medicine Treatments on Patients With Brain Cancer: A Pilot Study

Resource links provided by NLM:


Further study details as provided by Noah Samuels, The Chaim Sheba Medical Center:

Primary Outcome Measures:
  • Measure Yourself Concerns and Wellbeing (MYCAW) study tool [ Time Frame: 6 months ]
    Patient-Reported Outcome Measure - Quality of Life Assessment

  • Functional Assessment of Cancer Therapy, Brain Cancer (FACT-Br) questionnaire [ Time Frame: 6 months ]
    Patient-Reported Outcome Measure - Quality of Life Assessment

  • Edmonton Symptom Assessment Scale (ESAS) [ Time Frame: 6 months ]
    Patient-Reported Outcome Measure - Quality of Life Assessment

  • European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30) [ Time Frame: 6 months ]
    Patient-Reported Outcome Measure - Quality of Life Assessment


Secondary Outcome Measures:
  • Adverse effects attributed to the complementary/integrative medicine treatments [ Time Frame: 6 months ]
    Relates to the safety of the complementary medicine treatments

  • RDI - relative dose intensity [ Time Frame: 6 months ]
    Reflects adherence to the conventional chemo-radiation treatment regimen


Estimated Enrollment: 40
Anticipated Study Start Date: January 1, 2018
Estimated Study Completion Date: December 31, 2019
Estimated Primary Completion Date: December 31, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Patients will be treated with acupuncture and/or touch therapies, this in parallel to their chemo-radiation regimen. These treatments will be administered twice-weekly during active chemo-radiation treatment (6 weeks), followed by once-weekly treatment throughout the remainder of the study period (6 months)
Other: Acupuncture

Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated "acupoints" in the skin, along the limbs and trunk areas.

Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.

Shiatsu: The application of localized pressure along designated points (similar to "acupoints") along the limbs and trunk areas.

Other Name: Touch Therapy - reflexology or Shiatsu

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patient aged 18 years and older
  • diagnosed with high grade glioma (stage III-IV)
  • following surgical intervention (tumor resection)
  • prior to chemo-radiation treatment
  • signing of informed consent form

Exclusion Criteria:

  • inability/unwillingness to sign informed consent form
  • unwillingness of treating oncologist to allow participation in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03185780

Contacts
Contact: Noah Samuels, MD 972-3-5307307 noah.samuels@sheba.health.gov.il

Sponsors and Collaborators
The Chaim Sheba Medical Center
Investigators
Principal Investigator: Noah Samuels, MD Tal Center for Integrative Oncology, Institute of Oncology, Chaim Sheba Medical Center, Israel
  More Information

Responsible Party: Noah Samuels, Medical Director, Tal Center for Integrative Oncology, Institute of Oncology, The Chaim Sheba Medical Center
ClinicalTrials.gov Identifier: NCT03185780     History of Changes
Other Study ID Numbers: ChaimShebaMC
Study First Received: June 8, 2017
Last Updated: June 11, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Noah Samuels, The Chaim Sheba Medical Center:
complementary/integrative medicine
glioblastoma
quality of life
adherence

Additional relevant MeSH terms:
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on September 19, 2017